Ocean Biomedical, Inc. Responds to Nasdaq Filing Notice
Ocean Biomedical, Inc. (NASDAQ: OCEA) has recently announced that it received a notification from The Nasdaq Stock Market LLC concerning its Quarterly Report on Form 10-Q for the period ending June 30, 2024. This notice indicates that the company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1).
Causes of the Delay
The delay in filing the Form 10-Q is due to issues previously disclosed regarding the submission of the company's 10-K for the year ending December 31, 2023. Ocean Biomedical is actively addressing these filing delays and working to resolve any compliance issues. The company recognizes the critical importance of timely financial reporting to maintain investor confidence and ensure transparency.
Compliance Requirements from Nasdaq
According to the notice from Nasdaq, the company has been informed of specific requirements it must meet to regain compliance with its filing obligations. Ocean Biomedical is required to submit a plan by September 3, 2024, detailing the steps it will take to rectify the compliance issue. Following this, the overdue Form 10-Q must be filed by October 14, 2024, along with the 10-K for December 31, 2023, and the Form 10-Q for the quarter ending March 31, 2024.
Potential Impact on Stock Listing
While the current notice does not immediately affect the listing or trading of Ocean Biomedical's common stock on Nasdaq, any continued delays in submitting the required reports could prompt further actions from the exchange. The company is dedicated to taking all necessary measures to fulfill its filing obligations and prevent any potential negative consequences for its stock listing.
About Ocean Biomedical, Inc.
Ocean Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutic solutions. The company employs a unique business strategy designed to accelerate the transition of promising research from laboratories into clinical applications. Ocean Biomedical collaborates with research universities and medical institutions to leverage scientific breakthroughs in healthcare.
Focus on Research and Development
The organization has pinpointed five high-potential discoveries aimed at addressing significant health challenges, including lung cancer, brain cancer, pulmonary fibrosis, and malaria prevention and treatment. The dedicated team at Ocean Biomedical is committed to tackling pressing global health issues through innovative research and clinical trials.
Contact Information
For inquiries, Ocean Biomedical's Investor Relations can be contacted via email at connect@oceanbiomedical.com. Kevin Kertscher serves as the Communications Director for the company and is available for further communication.
Frequently Asked Questions
What prompted the Nasdaq notice to Ocean Biomedical?
The notice was issued because Ocean Biomedical failed to submit the Quarterly Report on Form 10-Q by the required deadline set by Nasdaq Listing Rules.
What actions must Ocean Biomedical take to regain compliance?
Ocean Biomedical is required to submit a compliance plan by September 3, 2024, and file the overdue Form 10-Q by October 14, 2024, along with the necessary 10-K reports.
Will the notice have any effect on Ocean Biomedical's stock trading?
At present, the notice does not affect stock trading; however, further delays in filing could lead to additional consequences that may impact the stock's status.
What research areas is Ocean Biomedical currently focusing on?
Ocean Biomedical is concentrating on developing therapies for lung cancer, brain cancer, pulmonary fibrosis, and malaria prevention and treatment.
Who should be contacted for more information about the company?
For further information or inquiries, the company's Investor Relations can be reached at connect@oceanbiomedical.com.